NCT01702012已完成不适用
Evaluation of Almased on Glycemic Control and Metabolic Effects in Patients With Type 2 Diabetes
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 240
- 试验地点
- 2
- 主要终点
- Change in HbA1c (%)
研究概览
简要总结
A 12 month multi-center randomization controlled study. Participants will be randomized to either a lifestyle education program or a meal replacement regimen with Almased, after an initial examination of eligibility criteria.
Primary outcome-HbA1c
详细描述
Age 21 + Male/Female gender Type 2 Diabetes Non-insulin dependent BMI 25-40 kg/m HbA1c 7.5-10%
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Gender: Men and women are eligible
- •Type 2 diabetes mellitus: Diabetes mellitus will be determined by medical records, current treatment, verification from personal health care provider, or test results meeting the 2010 American Diabetes Association criteria of fasting glucose ≥126 mg/dl, symptoms of hyperglycemia with casual plasma glucose > 200 mg/dl or two-hour plasma glucose ≥200 mg/dl after a 75 gram oral glucose load. Individuals who have a clinical history strongly suggestive of type 1 diabetes will be excluded. Individuals taking oral hypoglycemic medication with diet and exercise are eligible. Subjects taking insulin will not be eligible for entry into the study.
- •Body mass index: Overweight and obese individuals, with body mass index 25 - 40 kg/m2, are eligible. Weight loss is recommended for overweight diabetic participants with one or more cardiovascular risk factors.
- •Age: Individuals older than 21 years are eligible.
- •Ethnicity: All ethnic groups are eligible for the study.
- •Blood pressure: AMDIT will enroll individuals whose blood pressure is under at least moderate control. For safety purposes, moderate control will be defined in this study as systolic values under 160 mm/Hg and diastolic values under 100 mm/Hg. Individuals whose blood pressure exceeds these levels during screening will be advised to seek treatment and may be re-evaluated following initiation of antihypertensive treatment.
- •Glycemic control: AMDIT will enroll individuals whose HbA1c is between 7.5 and 10%. Individuals whose HbA1c exceeds this level may require more urgent care and will be told to seek treatment and may also be re-evaluated for inclusion.
- •Lipid control: Individuals with a fasting triglycerides concentration less than 500 mg/dl are eligible.
- •Willingness to participate: Participants must be willing to be randomized to either Almased or the Lifestyle Intervention and to follow the protocol to which they have been assigned. Individuals must be willing to modify their diet and their activity if they are assigned to the Lifestyle Intervention.
排除标准
- •Unable or unwilling to give informed consent or communicate with local study staff;
- •Psychotic disorders or bipolar disorders, hospitalization for depression in past six months;
- •Self-report of alcohol or substance abuse within the past twelve months, current consumption of more than 14 alcoholic drinks per week, and/or current acute treatment or rehabilitation program for these problems;
- •Plans to relocate to an area not served by AMDIT or travel plans that do not permit full participation in the study;
- •Known allergies to soy or dairy;
- •Current use of medications for weight loss;
- •Self-reported inability to walk two blocks;
- •History of bariatric surgery, small bowel resection, or extensive bowel resection;
- •Chronic treatment with systemic corticosteroids as weight gain associated with steroids may interfere with the intervention goals;
- •Candidates who have definite plans to move out of the area within the study period;
- •Candidates with any dietary practice, behavior, or attitude that would substantially limit adherence to the intervention;
- •Currently pregnant or nursing;
- •Cancer requiring treatment in the past five years, except for non-melanoma skin cancers or cancers that have clearly been cured or in the opinion of the investigator carry an excellent prognosis (e.g. Stage 1 cervical cancer);
- •HIV positive (self-report), due to effects on weight and body composition of HIV and medications used to treat HIV;
- •Active tuberculosis (self-report);
- •Cardiovascular or cardiopulmonary disease including a heart attack or procedure within the past three months; participation in a cardiac rehabilitation program within last three months; stroke or history/treatment for transient ischemic attacks in the past three months; documented history of pulmonary embolus in past six months; unstable angina pectoris or angina pectoris at rest; known history of cardiac arrest; known history of complex ventricular arrhythmia at rest or with exercise; known history of uncontrolled atrial fibrillation (heart rate of 100 beats per minute or more); known history of NYHA Class III or IV congestive heart failure; known history of acute myocarditis, pericarditis or hypertrophic myocardiopathy; known history of clinically significant aortic stenosis; known history of left bundle branch block or cardiac pacemaker unless evaluated by a cardiologist; cardiac defibrillator; heart transplant; known history of aortic aneurysm of at least 7 cm in diameter or aortic aneurysm repair;
- •Renal disease: urine dipstick protein of 4+ (equivalent to approximately > 1 g/day), serum creatinine exceeding 1.4 mg/dl (women) or 1.5 mg/dl (men), or currently receiving dialysis;
- •Known history of chronic obstructive pulmonary disease that would limit ability to follow the protocol;
- •Self-reported chronic hepatitis B or C or cirrhosis;
- •Inflammatory bowel disease requiring treatment in the past year;
- •Known history of Cushing's syndrome (clinic diagnosis or self-report);
- •Known history of Acromegaly (clinical diagnosis or self-report);
- •Amputation of lower limbs as result of non-traumatic causes;
- •Any major organ transplant (does not include cornea or hair transplants);
- •Conditions not specifically mentioned above may serve as criteria for exclusion at the discretion of the clinical site.
结局指标
主要结局
Change in HbA1c (%)
时间窗: 2, 4, 6, 8, 10, and 12 months
次要结局
- Change in HOMA IR Index(2, 4, 6, 8, 10, and 12 months)
- Change in fasting blood glucose (mg/dl)(2, 4, 6, 8, 10, and 12 months)
研究者
研究点 (2)
Loading locations...
相似试验
尚未招募
4 期
Effect of soya protein powder ALMASED on Diabetic patientsObesityCTRI/2011/11/002152Almased Wellness GmbH240
已完成
4 期
Trial to Evaluate the Efficacy on Glycemic Variability and Safety of Gemigliptin Compared With Dapagliflozin Added on Metformin Alone or Diabetes Medication Naïve Patient in Type 2 Diabetes Mellitus (Stable II Study)Type 2 Diabetes MellitusNCT03202563LG Chem71
Unknown
不适用
The Mobile Diabetes Mgmt. Study With Type 2 DiabetesType 2 DiabetesNCT02451631Healthconnect184
已完成
4 期
A Type 2 Diabetes Study of the Longer-Term Glycemic Effect of AVANDAMET vs. MetforminDiabetes Mellitus, Type 2NCT00386100GlaxoSmithKline688
已完成
3 期
A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.Diabetes Mellitus Type 2NCT00744367Hoffmann-La Roche326